Price comparison of capmatinib, a new drug for the treatment of MET-mutated non-small cell lung cancer, in different countries

1. R&D background and global status of capmatinib

Capmatinib (Capmatinib, trade name Tabrecta) is a kinase inhibitor targeting the MET gene developed by Novartis. As the first FDA-approved drug specifically targeting MET exon 14 skipping mutations (METex14 skipping), capmatinib fills an important gap in the precision treatment of non-small cell lung cancer (NSCLC). As the molecular classification of lung cancer continues to be refined, the emergence of capmatinib has given some patients who previously lacked effective treatment options new hope for survival.

xa0

2. Analysis of the latest indications of capmatinib

CurrentlyBoth the FDA and EMA have approved capmatinib for adult patients with metastatic non-small cell lung cancer and MET exon 14 skipping mutations. It is worth noting that its potential value in MET gene amplified NSCLC, gastric cancer, liver cancer and other solid tumors is also being explored. With the popularization of second- and third-generation sequencing technologies, the molecular characteristics of more patients can be accurately identified, thereby expanding the clinical applicable population of capmatinib.

xa0

3. Progress in clinical practice of usage and dosage

1. Pre-medication genetic testing: Precisely screen those who will benefit

All patients need to have METex14 mutations confirmed byFDA-approved testing methods (such as tissue or plasma NGS). If the plasma test is negative, further tumor tissue testing is recommended to avoid missed diagnosis.

2. Recommended dosage and administration method

Standard dosage: Oral administration400mg twice daily, taken with food or on an empty stomach.

Treatment of missed doses: If you miss a dose or vomit, there is no need to make up the dose. Take the next dose as originally planned to avoid increased toxicity caused by dose superposition.

Dose adjustment: Adjustment is divided into three levels according to the severity of adverse reactions:

Level 1 adjustment: reduce the dosage to 300mg bid (150mg×2 tablets)

Level 2 adjustment: reduce the dosage to 200mg bid (100mg×2 tablets)

Level 3 adjustment: intolerablePermanent discontinuation of 200mg bid patients

Special groups:

No dose adjustment is required in patients with mild to moderate renal impairment;

Patients with hepatic insufficiency need to closely monitor transaminases, and patients with severe liver damage should use with caution;

The elderly (≥65 years old) do not need to adjust the dose, but need to strengthen adverse reaction monitoring.

xa0

4. Innovative interpretation of the mechanism of action

Capmatinib inhibits with high selectivityMET tyrosine kinase blocks its downstream signaling pathways such as PI3K/AKT and RAS/MAPK. METex14 skipping mutations can lead to deletion of the protein regulatory region, resulting in continuous activation of MET, thereby driving unlimited proliferation of tumor cells. Capmatinib achieves precise inhibition by targeting this abnormal mechanism. This mode of action not only represents the concept of precision medicine, but also provides ideas for the subsequent development of more MET inhibitors.

xa0

5. Clinical efficacy and latest progress

In global multicenter studies, capmatinib demonstrated high objective response rates (ORR) and durable response times. For patients who have not received previous treatment, some studies show that the response rate even exceeds 60%. In addition, capmatinib exhibits good central nervous system penetration in patients with brain metastases, providing a new treatment option for this high-risk population. The latest real-world data (RWD) also shows that capmatinib still maintains high efficacy in Asian populations, further verifying its global application value.

xa0

6. Adverse reactions and management strategies

The most common adverse reactions include edema, nausea, fatigue, and musculoskeletal pain. Although some patients will develop serious adverse reactions such as interstitial lung disease (ILD) and abnormal liver function, most of them can be controlled through timely monitoring and dose adjustment. Expert consensus currently suggests that when using capmatinib, dynamic monitoring of liver function, pulmonary function and imaging should be strengthened to ensure long-term patient benefit.

xa0

7. Price and market structure of capmatinib

In China, capmatinib has been included in medical insurance, and the proportion of patients paying out of pocket has dropped significantly. The common specifications are200mg/tablet, and the price of different packaging is between 20,000 and 30,000 yuan/box. Original drugs in overseas markets are usually priced at about 50,000 yuan per month, which is expensive. In contrast, generic drugs in Laos and other places have gradually been launched, and the price has been significantly reduced to about 2,000 yuan per box, which has greatly improved patient accessibility. In the future, as more generic drugs are launched on the market, prices are expected to fall further, thereby promoting popularization and application worldwide.

xa0

8. Competitive landscape between capmatinib and other targeted drugs

Among theMET pathway drugs, in addition to capmatinib, Tepotinib has also been approved in some countries. The two are relatively close in terms of efficacy and safety, but there are differences in medical insurance coverage, price, accessibility, etc. In the future, the market structure may gradually shift from "multi-drug coexistence" to "individualized selection", where doctors will decide on specific medications based on the patient's clinical characteristics and tolerance.

xa0

9. Combination medication and future research directions

With the emergence of drug resistance, monotherapy often fails to maintain long-term efficacy. Therefore, combined treatment models have become a research hotspot. For example, combining capmatinib with immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) is expected to improve the tumor microenvironment and thereby prolong patient survival. Other studies are exploring combinations with EGFR inhibitors, anti-angiogenic drugs, etc., in order to overcome drug resistance and enhance efficacy. In the future, capmatinib may no longer be limited to monotherapy, but will serve as an important part of a combination treatment system to promote the further development of precision treatment of NSCLC.

xa0

10. Real world case sharing

A 70-year-old male patient was diagnosed with METex14 skip mutation metastatic NSCLC due to poor physical condition and could not tolerate traditional chemotherapy. After receiving capmatinib treatment for 3 months, the patient's imaging examination showed that the lesions were significantly reduced, and symptoms such as cough and shortness of breath were also significantly improved. The main side effects were mild edema, which was tolerated after symptomatic treatment with diuretics. Another female patient from Europe had a complicated condition due to brain metastasis. After using capmatinib, not only the lung tumor was controlled, but the brain metastases were also significantly reduced. These real-world cases provide strong support for the clinical application of capmatinib and also suggest its potential value in a variety of complex clinical scenarios.

xa0

xa0

11. Combining current affairs: promotion of precision medicine and medical insurance policies

In recent years, China’s introduction of innovative targeted drugs and medical insurance negotiations have accelerated. The inclusion of capmatinib in medical insurance not only reduces the financial burden on patients, but also reflects the country's emphasis on precision medicine. At the same time, with the popularity of NGS testing worldwide, more potential patients can be discovered in time, further enhancing the application value of capmatinib. Especially in the context of "chronic cancer" gradually becoming a consensus, capmatinib is becoming an important part of precision medicine.

Overseas reference materials:

FDA Official Website-Tabrecta (Capmatinib): https://www.fda.gov

Novartis Tabrecta Prescribing Information: https://www.novartis.com

National Cancer Institute-MET Inhibitors Overview: https://www.cancer.gov

European Society for Medical Oncology (ESMO)-Targeted Therapies Updates: https://www.esmo.org